Ascentage Gets US, China Nod for Novel Resistance-Fighting Cancer Drug

ROCKVILLE, Md. and SUZHOU, China – February 05, 2026 – By Matthew Richardson

Ascentage Pharma has secured a critical dual victory in its quest to develop next-generation cancer therapies, receiving Investigational New Drug (IND) clearance from both the U.S. Food and Drug Administration (FDA) and the China Center for Drug Evaluation (CDE) for its novel drug candidate, APG-3288. The back-to-back approvals pave the way for global clinical trials of a therapy designed to combat some of the most stubborn and resistant forms of blood cancer.

The drug, a Bruton's tyrosine kinase (BTK) targeted protein degrader, represents a new frontier in oncology. It is poised to enter a multicenter, open-label Phase I study to evaluate its safety and preliminary efficacy in patients with relapsed or refractory hematologic malignancies. For patients who have exhausted existing treatments, this new approach offers a potential lifeline.

“After receiving IND clearances for APG-3288 from the U.S. FDA and then the China CDE, we have reached a significant milestone in the field of targeted protein degradation, taking another major step forward with our global innovation strategy,” said Yifan Zhai, M.D., Ph.D., Chief Medical Officer of Ascentage Pharma. “We will expeditiously advance this global clinical development program for APG-3288... in efforts to bring this innovative therapeutic to patients in China and around the world as soon as possible.”

A New Weapon: Hijacking the Cell's Disposal System

APG-3288 is not a conventional inhibitor. Instead of simply blocking the BTK protein—a key driver in the growth of many B-cell cancers like chronic lymphocytic leukemia (CLL) and mantle cell lymphoma—it eliminates it entirely. The drug utilizes Ascentage Pharma's proprietary proteolysis-targeting chimera (PROTAC) technology, a sophisticated molecular strategy that essentially tags the BTK protein for destruction.

PROTACs are bifunctional molecules. One end latches onto the target protein (BTK), while the other recruits an E3 ubiquitin ligase, a component of the cell's natural protein disposal machinery. This forms a complex that flags the BTK protein as cellular waste, leading to its swift degradation by the proteasome. This catalytic process means a single molecule of APG-3288 can trigger the destruction of multiple BTK proteins, potentially leading to a more profound and sustained therapeutic effect at lower doses.

The key advantage of this degradation approach is its potential to overcome drug resistance. Many patients on existing BTK inhibitors, such as ibrutinib, eventually develop mutations (like the C481S mutation) that allow the cancer to circumvent the drug's blocking action. Because APG-3288 destroys the entire protein, it is designed to be effective against both the original, wild-type BTK and its mutated, resistant forms. This mechanism directly addresses one of the most significant challenges in the long-term management of B-cell malignancies.

Navigating a Competitive and Evolving Landscape

The market for BTK-targeted therapies is a multi-billion dollar arena dominated by major pharmaceutical players. First- and second-generation inhibitors like Imbruvica and Calquence have transformed treatment but are increasingly challenged by resistance. Even newer non-covalent inhibitors like Jaypirca, which can overcome some resistance mutations, are not a panacea.

This has spurred a race to develop BTK degraders, with several biotech firms like Nurix Therapeutics and BeiGene also advancing candidates through clinical trials. The scientific consensus is that targeted protein degradation is not just an incremental improvement but a transformative shift in drug development. Experts believe this class of drugs could fundamentally change the treatment paradigm for patients who have failed multiple lines of therapy.

“Protein degraders represent a new class of drugs, distinct from small molecule inhibitors,” noted one leading hematologist at a major U.S. cancer center, speaking on the general technology. “The ability to shuttle a target protein to the proteasome for complete elimination could overcome resistance mechanisms that have plagued us for years. This is a very promising strategy for our most difficult-to-treat patients.”

Ascentage Pharma's ability to secure simultaneous clearances in the world's two largest pharmaceutical markets—the U.S. and China—positions it as a formidable player in this innovative space. It highlights the company's robust global development capabilities and strategic foresight.

Ascentage's Strategic Trifecta in Blood Cancer

The IND clearance for APG-3288 is not an isolated event but a calculated step in Ascentage Pharma's broader strategy to become a leader in hematologic oncology. The company already has two approved and commercialized products in China: Olverembatinib, a third-generation inhibitor for chronic myeloid leukemia (CML), and Lisaftoclax, a novel Bcl-2 inhibitor for CLL.

These existing approvals provide Ascentage with invaluable experience in navigating regulatory pathways and establishing a commercial footprint in China. This foundation will be crucial for the future development and potential launch of APG-3288. Furthermore, the company’s deep pipeline allows for future exploration of combination therapies. The potential to pair a BTK degrader like APG-3288 with a Bcl-2 inhibitor like Lisaftoclax could create powerful, synergistic treatments that attack cancer from multiple angles.

With global Phase III trials already underway for its other lead assets, Ascentage is building a comprehensive portfolio aimed at addressing unmet needs across a spectrum of blood cancers. The addition of a next-generation protein degrader diversifies its technological approach and strengthens its long-term competitive position.

The upcoming Phase I trial for APG-3288 will be the first crucial test of its potential in human patients. Researchers will closely monitor its safety, tolerability, and pharmacokinetic profile while looking for early signs of efficacy. For the thousands of patients with relapsed and refractory B-cell malignancies, the start of this trial represents a new beacon of hope on the horizon.